Global Pharma R&D Returns Rise as GLP-1 Drugs Drive Forecast Growth
Global pharma R&D returns rise as GLP-1 therapies lift revenue forecasts through 2028; analysts expect higher ROI, reallocated capital to late-stage pipelines and improved profit margins.